Abstract:This article describes the rationale, objectives, design and conduct of the ambulatory blood pressure monitoring (ABPM)-based Hygia Project. Given the substantial evidence of the significantly better prognostic value of ABPM compared to clinic BP measurements, several international guidelines now propose ABPM as a requirement to confirm the office diagnosis of hypertension. Nonetheless, all previous ABPM outcome investigations, except the Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares study (MAPEC) study, relied upon only a single, low-reproducible 24 h ABPM assessment per participant done at study inclusion, thus precluding the opportunity to explore the potential reduction in cardiovascular disease (CVD) risk associated with modification of prognostic ABPM-derived parameters by hypertension therapy. The findings of the single-center MAPEC study, based upon periodic systematic 48 h ABPM evaluation of all participants during a median follow-up of 5.6 years, constitute the first proof-of-concept evidence that the progressive reduction of the asleep systolic blood pressure (SBP) mean and correction of the sleep-time relative SBP decline toward the normal dipper BP profile, most efficiently accomplished by a bedtime hypertension treatment strategy, best attenuates the risk of CVD, stroke and development of new-onset diabetes. The Hygia Project, primarily designed to extend the use of ABPM in primary care as a requirement for diagnosis of hypertension, evaluation of response to treatment and individualized assessment of CVD and other risks, is a research network presently composed of 40 clinical sites and 292 investigators. Its main objectives are to (i) investigate whether specific treatment-induced changes in ABPM-derived parameters reduce risk of CVD events, stroke, new-onset diabetes and/or development of chronic kidney disease (CKD); and (ii) test the hypothesis that bedtime chronotherapy entailing the entire daily dose of ≥1 conventional hypertension medications exerts better ambulatory BP control and CVD, metabolic and renal risk reduction than all such medications ingested in the morning upon awakening. Between 2007 and 2015, investigators recruited 18 078 persons [9769 men/8309 women, 59.1 ± 14.3 years of age (mean ± SD)], including 15 764 with hypertension according to ABPM criteria as participants in the prospective randomized chronotherapy trial. The initial evaluation includes 48 h ABPM, detailed medical history and screening laboratory blood and urine tests. The same evaluation procedure is scheduled annually, or more frequently when treatment adjustment is required for proper ambulatory BP control, targeting a median follow-up of >5 years. The primary CVD outcome end point is the composite of CVD death, myocardial infarction, coronary revascularization, heart failure, ischemic stroke and hemorrhagic stroke. The independent Hygia Project Events Committee periodically evaluates blinded clinical reports to ascertain and certify every documented event. Beyond the potential findings resulting from testing the main hypotheses, the Hygia Project has already demonstrated, as proof of concept, that the routine diagnosis of hypertension and individualized assessment of CVD and other risks by ABPM, as currently recommended, is fully viable in the primary care setting, where most people with either hypertension, dyslipidemia, type 2 diabetes or CKD receive routine medical attention.

Clinical Application of a Novel Automatic Algorithm for Actigraphy-Based Activity and Rest Period Identification to Accurately Determine Awake and Asleep Ambulatory Blood Pressure Parameters and Cardiovascular Risk

Evaluating Novel Approaches for Estimating Awake and Sleep Blood Pressure: Design of the Better BP Study – a Randomised, Crossover Trial

Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project

1131 : A Novel Sensor to Track Transient Blood Pressure Changes During Sleep

Application of Machine Learning Methods to Ambulatory Circadian Monitoring (ACM) for Discriminating Sleep and Circadian Disorders

The OXIMAPA Study: Hypertension Control by ABPM and Association with Sleep Apnea Syndrome by Pulse Oximetry

METHODOLOGICAL AND DIAGNOSTIC RELIABILITY OF 24-H ABPM: A PARADIGM SHIFT IN DAILY CLINICAL PRACTICE?

COMPARATIVE EVALUATION OF THE AKTIIA CUFFLESS MONITOR AND STANDARD 24-H AMBULATORY BLOOD PRESSURE MONITOR

O20 CURRENT 24-HOUR AMBULATORY BLOOD PRESSURE TECHNOLOGIES SHOULD BE RECONSIDERED AS THE REFERENCE STANDARD FOR VALIDATION OF CUFFLESS BLOOD PRESSURE DEVICES

Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry

In-Home, Smart Sleep Monitoring System for Cardiorespiratory Estimation and Sleep Apnea Detection: Proof of Concept

THE AGREEMENT BETWEEN HEART RATE MEASURED USING UNATTENDED AUTOMATED BLOOD PRESSURE MEASUREMENT AND OTHER METHODS OF BLOOD PRESSURE ASSESSMENT

Estimating sleep parameters using an accelerometer without sleep diary

A Hidden Markov Model Based Unsupervised Algorithm for Sleep/Wake Identification Using Actigraphy

EXERCISE AS MEDICINE; CHRONOTHERAPY IN HYPERTENSION MANAGEMENT

Reliable Contactless Monitoring of Heart Rate, Breathing Rate, and Breathing Disturbance During Sleep in Aging: Digital Health Technology Evaluation Study

Autonomic arousal detection and cardio-respiratory sleep staging improve the accuracy of home sleep apnea tests

The evolving role of quantitative actigraphy in clinical sleep medicine

Validation of actigraphy sleep metrics in children aged 8 to 16 years: considerations for device type, placement and algorithms

Simultaneous 24-h ambulatory blood pressure measurement on both arms: a consideration for improving hypertension management

1015 Evaluation of Actigraphy Sensors: Detecting Daytime Sleep After Stroke in an Inpatient Rehabilitation Hospital